SNBL USA,the experts in nonhuman primate (NHP) toxicology, is pleased to announce the addition of three experienced business development professionals to its team.
Terry Ladd, MA, MBA joins SNBL USA as a Senior Director of Business Development and will be responsible for the business development operations for Eastern Canada and the New England region of the United States. With over 20 years of business development experience in the preclinical field, Mr. Ladd has held senior management positions in business development and marketing and has previously worked with Calvert Laboratories, Inc., MDS Pharma Services, Inc. and SkeleTech, Inc., among others.
Kirk Randall joins the team as a Director of Business Development and will focus business development strategy and execution in the Midwestern United States. Mr. Randall has over 20 years industry experience in the preclinical and pharmaceutical fields and is well-versed in many areas of the drug development process. Prior to joining SNBL USA, he has held similar positions at Viacor-IBT Laboratories, MPI Research, LLC. and Ortho Biotech, Inc.
Amanda Grewal is a Business Development Manager targeting business development efforts in the San Francisco Bay and surrounding areas. She brings over 10 years of business development experience as well as a solid understanding of the pharmaceutical industry. Before joining SNBL USA, Ms. Grewal has held various business development at SGS, Charles River, AJ Process and Chiron.
"Terry, Kirk, and Amanda represent seasoned, successful professionals with consummate preclinical business development expertise," said Mark Crane, Vice President of Business Development, SNBL USA. "We believe their deep understanding of the industry along with the additional geographical coverage will increase SNBL USA's market presence and expand the reach of our services and expertise to new and existing clients and markets."
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. offers a unique range of safety assessment services to fulfill our commitment of freeing patients from suffering. Managed and operated by a team world renowned for its wide-ranging NHP experience and expertise, we offer programs ranging from regulatory toxicology to customized study designs. Our specialized capabilities include safety assessment of biologics, reproductive toxicology, cardiovascular, respiratory and CNS pharmacology, immunotoxicology and carcinogenicity. SNBL USA's state of the art facility can house nearly 4,000 NHPs. Our available in house colony assures a quick study start. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. With its multiple worldwide facilities and countless skilled and experienced scientists and technicians SNBL Group works together in providing a full range of drug development services.
SNBL USA, Ltd.
Michelle Taylor, MA, 425-322-1950